The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03723369|
Recruitment Status : Recruiting
First Posted : October 29, 2018
Last Update Posted : April 30, 2019
Androgenetic alopecia is the most common type of hair loss in men, and affects approximately 50 percent of Caucasian men by age 50. The condition is characterized by the progressive loss of terminal hairs on the scalp in a characteristic distribution. The anterior scalp, mid scalp, temporal scalp, and vertex of the scalp are typical sites of involvement. "Male balding" and "male pattern hair loss" are additional terms used to refer to this condition.
The aim of this study is to investigate the effect of microneedling in androgenic alopecia
|Condition or disease||Intervention/treatment||Phase|
|Dermatologic Disease||Device: accupuncture||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients.|
|Actual Study Start Date :||October 30, 2018|
|Estimated Primary Completion Date :||October 30, 2019|
|Estimated Study Completion Date :||December 30, 2020|
- Device: accupuncture
- hair regrowth(7-point rating scale (-3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).) [ Time Frame: 12weeks ]hair regrowth(7-point rating scale (-3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03723369
|Contact: Gong Yau Chu, MD||886 email@example.com|
|Contact: Gong Yau Chu, MD|